Ziopharm Oncology Inc. presented new interim analyses of clinical data from two ongoing sub-studies in its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults.  “Profiling an expanded number of patients with rGBM shows that Controlled IL-12 engages patients’ immune systems which we previously showed was an indicator of improved overa...